M&T Bank Corp acquired a new position in shares of Genmab A/S (NASDAQ:GMAB – Get Rating) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 17,080 shares of the company’s stock, valued at approximately $503,000.
Several other large investors also recently bought and sold shares of the stock. Alliancebernstein L.P. purchased a new stake in Genmab A/S during the third quarter worth $185,695,000. BlackRock Inc. boosted its stake in Genmab A/S by 1.6% during the first quarter. BlackRock Inc. now owns 5,494,689 shares of the company’s stock worth $198,799,000 after buying an additional 86,571 shares during the period. Capital International Investors boosted its stake in Genmab A/S by 7.7% during the first quarter. Capital International Investors now owns 3,952,446 shares of the company’s stock worth $145,433,000 after buying an additional 283,031 shares during the period. Wellington Management Group LLP boosted its stake in shares of Genmab A/S by 5.8% in the first quarter. Wellington Management Group LLP now owns 3,333,824 shares of the company’s stock valued at $120,618,000 after purchasing an additional 183,578 shares during the period. Finally, First Trust Advisors LP purchased a new position in shares of Genmab A/S in the third quarter valued at approximately $41,496,000. Hedge funds and other institutional investors own 6.73% of the company’s stock.
Analyst Ratings Changes
GMAB has been the topic of several analyst reports. HC Wainwright raised their target price on shares of Genmab A/S from $47.00 to $51.00 in a report on Monday, May 22nd. Morgan Stanley started coverage on shares of Genmab A/S in a research note on Friday, May 12th. They set an “underweight” rating on the stock. UBS Group started coverage on shares of Genmab A/S in a research note on Wednesday, May 31st. They issued a “neutral” rating on the stock. Danske upgraded shares of Genmab A/S from a “hold” rating to a “buy” rating in a report on Thursday, February 23rd. Finally, SVB Leerink raised their price target on shares of Genmab A/S from $33.00 to $36.00 and gave the company a “market perform” rating in a report on Monday, February 6th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $632.62.
Genmab A/S Trading Up 0.6 %
About Genmab A/S
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia.
Featured Stories
- Get a free copy of the StockNews.com research report on Genmab A/S (GMAB)
- Will Nvidia Be the Lifeline Intel Desperately Needs?
- Is Li Auto Head and Shoulders Above Its Chinese Counterparts?
- MarketBeat Week in Review – 5/29 – 6/2
- Trading Channel Breakout in Lululemon Brought by Earnings
- What Should Investors Make of These 3 Dividend Cuts?
Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S (NASDAQ:GMAB – Get Rating).
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
